RESUMO
The epidermis functions as a physical barrier that separates the inner body from the outside environment. The outermost layer of the epidermis, the stratum corneum, plays a key role in maintaining this barrier. There are numerous biochemical changes that take place to and in the keratinocyte as it migrates from the bottom, or startum basale, to the top layer of the epidermis in order for this barrier to function appropriately. In addition, external and internal factors, such as irritants and underlying medical diseases, can also affect the stratum corneum, both of which can potentially lead to disruption of barrier function and ultimately skin pathology. In this article, we will review keratinocyte biology as it relates to the formation and function of the stratum corneum. We will also review stratum corneum structure, physiology, and the impact of chemical agents and defective stratum corneum components that can lead to skin disease. Finally, we will briefly discuss how moisturizers repair defects in the stratum corneum and restore barrier function.
J Drugs Dermatol. 2016;15(9):1047-1051.
Assuntos
Cosméticos/administração & dosagem , Epiderme/efeitos dos fármacos , Epiderme/fisiologia , Nível de Saúde , Medicamentos sem Prescrição/administração & dosagem , Higiene da Pele/métodos , Cosméticos/metabolismo , Epiderme/patologia , Homeostase/efeitos dos fármacos , Homeostase/fisiologia , Humanos , Medicamentos sem Prescrição/metabolismo , Dermatopatias/tratamento farmacológico , Dermatopatias/metabolismo , Dermatopatias/patologiaRESUMO
PURPOSE: To assess possible origins of harmful interactions in elderly patients arising from the current absence of information on over-the-counter (OTC) medicines in the Danish 'on-line prescription record'. METHODS: Information on current use of prescription drugs and OTC medicinal products (non-prescription drugs, herbal medicine, dietary supplements, and others) was collected by home visit interviews. The latter OTC products were not listed in an on-line prescription record that covered the previous two years. Information on interactions between OTC medicines and between OTC products and prescription drugs was obtained from the Danish National Drug Interaction Database. RESULTS: Of the 309 patients recruited (median age 75 years, interquartile range (IQR) 70-81), 229 (74%) used 568 OTC medicines not listed in the Danish 'on-line prescription record', amongst which we identified 166 potential interactions - between OTC treatments or between OTC and prescription drugs. Fifty percent of patients taking OTC medicines were exposed to potential interactions, i.e. one to three instances per patient. Twenty-five percent of patients exposed to interactions experienced interaction listed as 'Can be used with certain precautions'. CONCLUSION: The absence of information on OTC products in an on-line prescription record entails a risk of overlooking interactions in elderly patients. Such products should be included in on-line medication records to prevent adverse effects from interactions. However, online medication records are not available in all countries and as inclusion of data on OTC drugs seem not to be feasible presently. Still, it is highly recommended that the patient's drug list is reviewed on a regular basis.
Assuntos
Interações Medicamentosas/fisiologia , Registros Eletrônicos de Saúde/normas , Registros de Saúde Pessoal , Medicamentos sem Prescrição/uso terapêutico , Medicamentos sob Prescrição/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Suplementos Nutricionais , Feminino , Humanos , Masculino , Medicamentos sem Prescrição/metabolismo , Preparações de Plantas/metabolismo , Preparações de Plantas/uso terapêutico , Medicamentos sob Prescrição/metabolismo , Estudos Prospectivos , Fatores de RiscoRESUMO
Retinitis pigmentosa (RP) is the most common genetic disorder that causes blindness. At present, there exists no remedy for the disease. The aim of the current research was to investigate the protective effect of Zhangyanming Tablets (ZYMT) in a mouse model of RP, and explore the underlying mechanism. Eighty RP mice were randomly divided into two groups. The mice in ZYMT group were administered with ZYMT suspension(0.0378 g/mL), while the mice in model group were given the same volume of distilled water. At day 7 and day 14 after intervention, electroretinogram (ERG), fundus photography, and histological examination were used to assess the retinal function and structure. TUNEL, immunofluorescence and qPCR were used to evaluate cell apoptosis and expressions of Sirt1, Iba1, Bcl-2, Bax and Caspase-3. A significantly shortened latency of ERG waves was observed in ZYMT-treated mice, in comparison to those in the model group (P < 0.05). Histologically, ultrastructure of the retina was better preserved, and the outer nuclear layer (ONL) exhibited marked increase in thickness and cell count in ZYMP group (P < 0.05). The apoptosis rate was decreased markedly in ZYMT group. Immunofluorescence analysis showed that the expressions of Iba1 and Bcl-2 in the retina were increased, Bax and Caspase-3 were decreased after ZYMT intervention, while the qPCR revealed that the expressions of Iba1 and Sirt1 were significantly increased (P < 0.05). This study indicated that ZYMT has protective effect on retinal function and morphology of inherited RP mice in the early stage, possibly mediated via the regulation of antioxidant and anti-/pro-apoptotic factors expressions.
Assuntos
Retinose Pigmentar , Sirtuína 1 , Camundongos , Animais , Sirtuína 1/metabolismo , Caspase 3/metabolismo , Proteína X Associada a bcl-2/metabolismo , Retinose Pigmentar/genética , Retinose Pigmentar/metabolismo , Retinose Pigmentar/patologia , Retina , Medicamentos sem Prescrição/metabolismo , Medicamentos sem Prescrição/farmacologia , Modelos Animais de DoençasRESUMO
Research on the active components of medicinal plants has always been the focus of research, and research on the active components of medicinal plant endophytic fungi and their secondary metabolites has also attracted widespread attention. Endophytic fungi of medicinal plants are widely distributed and are ubiquitous in various biological groups in nature. Rehmannia glutinosa contains a variety of active ingredients, which are regarded as the top grade of Chinese medicinal materials. It is of certain significance to study endophytic fungi and their metabolites of Rehmannia glutinosa. In this paper, endophytic fungi and their secondary metabolites of Rehmannia glutinosa were studied using fingerprint technology, which initially understands the diversity of endophytic fungi in Rehmannia glutinosa. In this paper, the roots and leaves of Rehmannia glutinosa were used as experimental materials. The fungi were cultured in the medium, the fungi were isolated and purified by the tissue block method, the fungal growth of Rehmannia glutinosa in different parts was determined, and the types of endophytic fungi were identified by microscopic identification and fingerprinting. The isolated strains were tested for biological activity using oryza oryzae spores, and highly active strains were screened. Fermentation products of endophytic fungi were separated and purified by chromatography, and the structure of the compounds was identified by nuclear magnetic resonance spectroscopy. Through the above studies, the population structure of endophytic fungi of Rehmannia glutinosa was determined, 3 highly active strains were found, and the structures of 7 endophytic fungi metabolites were identified, of which 3 were newly discovered compounds.
Assuntos
Rehmannia , Fungos/metabolismo , Medicina Tradicional Chinesa , Medicamentos sem Prescrição/metabolismo , Raízes de Plantas/microbiologia , Rehmannia/microbiologiaRESUMO
Many medicines available over the counter from pharmacies are known to have abuse potential, including diphenhydramine (DPH), an antihistamine with antimuscarinic properties used for the treatment of insomnia. We present a brief review of the literature describing DPH abuse, and report the case of GF, a 56 year old woman who was admitted to an inpatient addictions unit for detoxification from DPH. A literature search revealed five case reports of DPH abuse including a total of six patients, published between 1986 and 2001. All reported cases exhibited features of DSM-IV criteria for substance dependence, and there was an apparent link with antipsychotic usage. GF was treated with antipsychotics, and was using up to thirty 50 mg DPH tablets each day. She described feeling 'good and calm' and 'it stopped the tremors'. GF tolerated a gradual dose reduction schedule, and completed the detoxification programme relatively comfortably. She was discharged from the inpatient detoxification unit as planned, and had not relapsed at six months. The described case report highlights the importance of enquiring about non prescribed medication when taking a drug history. Similarly community pharmacists and GPs should be vigilant to excessive requests for DPH, particularly in patients with a psychotic illness.
Assuntos
Difenidramina/metabolismo , Difenidramina/toxicidade , Antagonistas dos Receptores Histamínicos/metabolismo , Antagonistas dos Receptores Histamínicos/toxicidade , Inativação Metabólica/fisiologia , Bases de Dados Bibliográficas , Manual Diagnóstico e Estatístico de Transtornos Mentais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Medicamentos sem Prescrição/metabolismo , Medicamentos sem Prescrição/toxicidade , Centros de Tratamento de Abuso de Substâncias , Fatores de TempoRESUMO
BACKGROUND: Oral lichen planus (OLP) is a chronic mucosal disease with a characteristic clinical phenotype. Environmental exposures, e.g. drugs have been associated with the pathogenesis. OBJECTIVES: To test the hypothesis that some OLP lesions have a pharmacological pathogenesis related to polymorphisms of the cytochrome P450 enzymes (CYPs) resulting in poor or intermediate CYP metabolism. METHODS: One hundred and twenty patients with OLP and 180 gender-matched controls without OLP were genotyped for CYP2C9, CYP2C19, and CYP2D6 alleles with absent or reduced function. RESULTS: The prevalence of poor or intermediate metabolizers was not higher among the OLPs as compared with the controls; however, there were higher numbers of variant CYP2D6 genotypes among the OLP females (P < 0.05). There were no differences between the groups with regard to intake of drugs metabolized by polymorphic CYPs or drug or herbal products inhibiting CYPs. The prevalence of CYP2D6*4 alleles among the OLPs was higher [28%; 95% confidence interval (CI) 20-36%] than previously reported among Danes (19%; 95% CI 17-22%). Fifty per cent of the OLPs had a CYP2D6*4 genotype as compared with 30% in the background population (P = 0.0001). The CYP2D6*4 protein has sequence homology with human herpes simplex virus type 1 (HSV1) and Candida albicans, which may result in molecular mimicry. CONCLUSION: It was not possible to substantiate a pharmacological pathogenesis of OLP based on poor or intermediate CYP metabolism. However, molecular mimicry between CYP2D6, in particular CYP2D6*4, and common oral pathogens may be involved in the pathogenesis of OLP.
Assuntos
Sistema Enzimático do Citocromo P-450/genética , Líquen Plano Bucal/enzimologia , Polimorfismo Genético/genética , Adulto , Idoso , Hidrocarboneto de Aril Hidroxilases/genética , Estudos de Casos e Controles , Estudos de Coortes , Citocromo P-450 CYP2C19 , Citocromo P-450 CYP2C9 , Citocromo P-450 CYP2D6/genética , Sistema Enzimático do Citocromo P-450/metabolismo , Suplementos Nutricionais , Feminino , Frequência do Gene , Variação Genética/genética , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Mimetismo Molecular/genética , Medicamentos sem Prescrição/metabolismo , Preparações Farmacêuticas/metabolismo , Plantas Medicinais/metabolismo , Estudos ProspectivosRESUMO
Sunscreens are regulated as over-the-counter drugs in the United States. Some sunscreen ingredients are absorbed into the systemic circulation, which raises concerns about the safety of these drugs. There is limited information on the systemic exposure for most sunscreen ingredients. This report estimates the systemic absorption of two sunscreen active ingredients, oxybenzone and enzacamene, by developing a pharmacokinetic model from published sunscreen absorption data and compares the results with safety thresholds proposed by the US Food and Drug Administration and in the literature. Our analysis indicates that systemic absorption can be substantial, and evaluation of the systemic exposure of sunscreen ingredients is warranted to better assess any long-term risks of use.
Assuntos
Benzofenonas/metabolismo , Cânfora/análogos & derivados , Modelos Biológicos , Absorção Cutânea/fisiologia , Protetores Solares/metabolismo , United States Food and Drug Administration/legislação & jurisprudência , Administração Tópica , Benzofenonas/administração & dosagem , Benzofenonas/efeitos adversos , Cânfora/administração & dosagem , Cânfora/efeitos adversos , Cânfora/metabolismo , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Medicamentos sem Prescrição/administração & dosagem , Medicamentos sem Prescrição/efeitos adversos , Medicamentos sem Prescrição/metabolismo , Absorção Cutânea/efeitos dos fármacos , Protetores Solares/administração & dosagem , Protetores Solares/efeitos adversos , Estados Unidos , Adulto JovemRESUMO
BACKGROUND: 5-hydroxyindoleacetic acid (5-HIAA) excretion is commonly measured for biochemical detection of carcinoid tumours. A 77-year-old woman was referred for elevated 24 h urine 5-HIAA excretion (510 micromol/day; normal is less than 45 micromol/day) and serum chromogranin A (CgA) (72.1 U/L; normal is less than 18 U/L), both subsequently normalized after discontinuation of 5-hydroxytryptophan (5-HTP). 5-HTP, a precursor of serotonin, is not commonly listed as a substance that increases 5-HIAA levels in urine. The effect of 5-HTP on CgA has not been previously described. OBJECTIVES: To determine whether, and to what extent, oral 5-HTP increases urine 5-HIAA excretion and serum CgA levels in healthy volunteers. PATIENTS AND METHODS: A randomized, prospective, double-blind, placebo-controlled crossover study, with a four-day washout period, was performed in a general community setting. Eight healthy subjects aged 22 to 58 years were recruited by advertising. Bedtime ingestion of 5-HTP 100 mg/day was compared with placebo ingestion for 10 days. Twenty-four hour urine excretion of 5-HIAA and serum CgA were the main outcome measures. RESULTS: Median (range) urinary 5-HIAA excretion was 204 micromol/day (22 micromol/day to 459 micromol/day) during 5-HTP intake, compared with 18 micromol/day (12 micromol/day to 36 micromol/day) during placebo intake (P=0.017). 5-HTP did not affect clinical symptoms or serum CgA levels. CONCLUSIONS: Oral 5-HTP increases urinary 5-HIAA excretion with considerable interindividual variation. In a small number of subjects, oral 5-HTP did not affect serum CgA levels. Therefore, increased 5-HIAA levels with normal CgA levels may suggest 5-HTP ingestion. The use of over-the-counter 5-HTP should be excluded as the cause of increased urinary 5-HIAA levels before initiating diagnostic tests to search for a carcinoid tumour. 5-HTP should be added to popular references as a substance that may cause increased 5-HIAA excretion.
Assuntos
5-Hidroxitriptofano/metabolismo , Biomarcadores/metabolismo , Cromogranina A/sangue , Ácido Hidroxi-Indolacético/urina , 5-Hidroxitriptofano/administração & dosagem , Adulto , Tumor Carcinoide/diagnóstico , Estudos Cross-Over , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Medicamentos sem Prescrição/administração & dosagem , Medicamentos sem Prescrição/metabolismo , Estudos ProspectivosRESUMO
The Montgomery County Coroner's Office has encountered a series of 10 infant deaths over an 8-month period in infants under 12 months old with toxicology findings that include a variety of drugs commonly found in over-the-counter (OTC) cold medications. The drugs detected were ephedrine, pseudoephedrine, dextromethorphan, diphenhydramine, chlorpheniramine, brompheniramine, ethanol, carbinoxamine, levorphanol, acetaminophen, and the anti-emetic metoclopramide. Toxicology findings were confirmed in 2 different matrices in 9 of the 10 cases and by 2 different analytical methods. The blood concentrations of the drugs and the case histories, as well as the cause of death for each infant, if available, will be given. The majority of these deaths were either toxicity from the OTC cold medications directly or as a contributory factor in the cause of death. Only two of the cases were the result of possible child abuse. Caregivers may be under the mistaken notion that OTC cold medications formulated for children are also safe for use in infants. These cases demonstrate that not only is administration of some OTC cold medications not safe, but use of OTC cold medications in infants can result in toxicity that can lead to death.
Assuntos
Causas de Morte , Resfriado Comum/tratamento farmacológico , Medicina Legal , Medicamentos sem Prescrição/toxicidade , Autopsia , Contraindicações , Médicos Legistas , Evolução Fatal , Humanos , Lactente , Medicamentos sem Prescrição/metabolismo , OhioRESUMO
Both carcinogenic and non-carcinogenic nitrosamines can be formed under physiological conditions in the human body by a reaction between nitrite and secondary or tertiary amines. A large number of people are exposed daily through drinking water to high levels of nitrate, which can be reduced to nitrite. Moreover, nitrate and nitrite are present in vegetables and nitrite is used in food preservation. Dietary exposure to amines is normally below 100 mg per day, whereas paracetamol and antazolin, both secondary amines, are used therapeutically at much higher doses. Knowledge about the possible interactions between these widely used drugs and the background exposure to nitrite is presently not available. Therefore, an evaluation of the carcinogenic hazard related to this combination is needed.
Assuntos
Nitrosaminas/metabolismo , Medicamentos sem Prescrição/metabolismo , Acetaminofen/metabolismo , Antagonistas Adrenérgicos alfa/metabolismo , Humanos , Imidazóis/metabolismo , Nitratos/metabolismo , Nitritos/metabolismo , Fenacetina/metabolismoRESUMO
BACKGROUND: Chlorpheniramine is known to cause drowsiness, and this side effect has a potential to impair performance and could be a factor in accidents. METHODS: Therefore, to establish the prevalence of this drug in pilot fatalities of aviation accidents, a postmortem toxicology database--maintained at the Civil Aeromedical Institute--was examined for the presence of chlorpheniramine in the fatalities, occurred during 1991-1996. RESULTS: There were 47 (2.2%) accidents involving chlorpheniramine. Of these, 16 had only chlorpheniramine at 109 ng.ml-1 (n = 4) in blood and 1412 ng.g-1 (n = 12) in liver. Other drugs were also present in the remaining 31 cases, wherein chlorpheniramine concentrations were 93 ng.ml-1 (n = 18) in blood and 747 ng.g-1 (n = 12) in liver. Ninety-five percent of all quantitated blood values were at or above the therapeutic level (10 ng.ml-1), giving a 100 ng.ml-1 (n = 21) mean blood value. The drug's mean liver concentration from all cases was 1080 ng.g-1 (n = 24). The average blood value was approximately 10 times higher than the therapeutic value. CONCLUSIONS: The presence of other drugs did not appear to significantly alter the blood chlorpheniramine level, but no such correlation could be established with the hepatic value. The approximate 10-fold increase in the liver concentration was consistent with the general trend of drug distribution in the hepatic compartment. However, the contribution of postmortem redistribution of the drug to alter its concentration cannot be entirely ruled out. This study suggests that chlorpheniramine was present in some aviation fatalities at levels higher than therapeutic levels.
Assuntos
Acidentes Aeronáuticos/mortalidade , Clorfeniramina/efeitos adversos , Antagonistas dos Receptores Histamínicos H1/efeitos adversos , Fases do Sono/efeitos dos fármacos , Acidentes Aeronáuticos/estatística & dados numéricos , Acidentes Aeronáuticos/tendências , Autopsia , Clorfeniramina/análise , Clorfeniramina/metabolismo , Antagonistas dos Receptores Histamínicos H1/análise , Antagonistas dos Receptores Histamínicos H1/metabolismo , Humanos , Fígado/química , Medicamentos sem Prescrição/efeitos adversos , Medicamentos sem Prescrição/análise , Medicamentos sem Prescrição/metabolismo , Vigilância da População , Prevalência , Fatores de Risco , Detecção do Abuso de Substâncias , Distribuição Tecidual , Estados Unidos/epidemiologiaRESUMO
AIDS: Dr. Charles Flexner, an Associate Professor at Johns Hopkins University, discusses different issues involving drug interactions. Flexner states that some interactions exist between street drugs and HIV medications, including between benzodiazepines and Ritonavir (Norvir) or Nelfinavir (Viracept). He also reports on toxicity and death cases associated with MDMA (ecstasy) and protease inhibitors. Drugs for opportunistic infections are also described; most are not implicated in clinically significant drug interactions, nor are most over-the-counter medications. Dr. Flexner's opinions on protease-sparing regimens and lipodystrophy are also provided.^ieng
Assuntos
Consumo de Bebidas Alcoólicas , Fármacos Anti-HIV/efeitos adversos , Sistema Enzimático do Citocromo P-450/metabolismo , Infecções por HIV/tratamento farmacológico , Inibidores da Protease de HIV/efeitos adversos , Drogas Ilícitas , Inibidores da Transcriptase Reversa/efeitos adversos , Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Fármacos Anti-HIV/metabolismo , Antituberculosos/efeitos adversos , Antituberculosos/metabolismo , Interações Medicamentosas , Inibidores da Protease de HIV/metabolismo , Humanos , Lipodistrofia/induzido quimicamente , Medicamentos sem Prescrição/efeitos adversos , Medicamentos sem Prescrição/metabolismo , Inibidores da Transcriptase Reversa/metabolismoRESUMO
Concomitant use of alcohol and medications may lead to potentially serious medical conditions. Increasing prescription medication abuse in today's society necessitates a deeper understanding of the mechanisms involved in alcohol-medication interactions in order to help prevent adverse events. Interactions of medications with alcohol result in altered bioavailability of the medication or alcohol (pharmacokinetic interactions) or modification of the effects at receptor or ion channel sites to alter behavioral or physical outcome (pharmacodynamic interactions). The nature of pharmacokinetic or pharmacodynamic interactions involved in alcohol-medication interactions may differ between acute and chronic alcohol use and be influenced by race, gender, or environmental or genetic factors. This review focuses on the mechanisms underlying pharmacokinetic and pharmacodynamic interactions between alcohol and medications and provides examples for such interactions from replicated research studies. In conclusion, further translational research is needed to address several gaps in our current knowledge of alcohol-medication interactions, including those under various pathologic conditions.
Assuntos
Consumo de Bebidas Alcoólicas/metabolismo , Interações Medicamentosas/fisiologia , Etanol/metabolismo , Medicamentos sem Prescrição/metabolismo , Medicamentos sob Prescrição/metabolismo , Consumo de Bebidas Alcoólicas/efeitos adversos , Animais , Etanol/efeitos adversos , Humanos , Medicamentos sem Prescrição/efeitos adversos , Medicamentos sob Prescrição/efeitos adversos , Transdução de Sinais/fisiologiaRESUMO
The kidney plays a major role in pharmacokinetics and pharmacodynamics of drugs; therefore, medication errors can result from failure to properly adjust medications in patients with CKD. It is the responsibility of all health-care providers to work collectively when reviewing medications, initiating new medications, and adjusting doses of current medications. Awareness of appropriate dosing recommendations can significantly decrease medication error-associated morbidity, mortality, and cost.
Assuntos
Injúria Renal Aguda/induzido quimicamente , Analgésicos Opioides/efeitos adversos , Anticoagulantes/efeitos adversos , Fármacos Gastrointestinais/efeitos adversos , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Hipoglicemiantes/efeitos adversos , Hipolipemiantes/efeitos adversos , Erros de Medicação/prevenção & controle , Medicamentos sem Prescrição/efeitos adversos , Insuficiência Renal Crônica/metabolismo , Injúria Renal Aguda/complicações , Analgésicos Opioides/metabolismo , Anticoagulantes/metabolismo , Fármacos Gastrointestinais/metabolismo , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/metabolismo , Hipoglicemiantes/metabolismo , Hipolipemiantes/metabolismo , Medicamentos sem Prescrição/metabolismo , Insuficiência Renal Crônica/complicaçõesRESUMO
We report two patients with markedly elevated 24-h urine 5-hydroxyindoleacetic acid (5-HIAA) excretion due to over-the-counter (OTC) self-medication with 5-hydroxytryptophan (5-HTP). It is important to recognize that OTC medication may cause increased 'false-positive' 5-HIAA excretion to prevent undue patient anxiety and unnecessary further investigation for carcinoid disease. Discordance between chromogranin A and 24-h urine 5-HIAA results should alert to the possibility of false-positive or -negative laboratory results.
Assuntos
5-Hidroxitriptofano/metabolismo , Ácido Hidroxi-Indolacético/urina , Medicamentos sem Prescrição/metabolismo , 5-Hidroxitriptofano/administração & dosagem , Idoso , Cromatografia Líquida de Alta Pressão , Cromogranina A/sangue , Reações Falso-Positivas , Feminino , Humanos , Síndrome do Carcinoide Maligno/diagnóstico , Síndrome do Carcinoide Maligno/urina , Pessoa de Meia-Idade , Medicamentos sem Prescrição/administração & dosagem , Serotonina/metabolismoRESUMO
Loxoprofen (Loxonin(®)), an antipyretic painkiller, was approved as an over-the-counter (OTC) drug (Loxonin(®)-S) in January 2011. With regard to self-medication using OTC drugs, the information that pharmacists provide to consumers is very important. Although loxoprofen is a very versatile drug and can be used during breastfeeding, information regarding its mammary gland transfer is inadequate. In this study, we established a simple method to evaluate mammary transfer of drugs, and compared loxoprofen's mammary gland transfer with that of aspirin. Loxoprofen 12 mg/kg and aspirin 132 mg/kg was orally administered to mother mice (ddY), and blood and milk samples were collected. Twenty microliters of ethanol was added to the blood and milk samples (10 µL), and the mixture was centrifuged for 15 min (12000 g); the supernatant was analyzed by high-performance liquid chromatography. Since aspirin was immediately metabolized, we analyzed salicylic acid concentrations. Maximum concentration of loxoprofen was observed at around 15 min after its oral administration, with the concentrations in the blood and milk being 2.9 and 0.5 µg/mL, respectively. The drug was metabolized promptly thereafter. In contrast, maximum concentration of salicylic acid was observed at 30 min after aspirin administration, with the concentrations in the blood and milk being 187.2 and 64.4 µg/mL, respectively. These concentrations remained constant from 60 to 120 min. Salicylic acid could be detected 240 min after aspirin administration. Thus, mammary gland transfer of loxoprofen is lower than that of aspirin, suggesting that loxoprofen does not accumulate in milk.
Assuntos
Anti-Inflamatórios não Esteroides/metabolismo , Cromatografia Líquida de Alta Pressão , Glândulas Mamárias Humanas/metabolismo , Medicamentos sem Prescrição/metabolismo , Fenilpropionatos/metabolismo , Animais , Aspirina/metabolismo , Feminino , Humanos , CamundongosRESUMO
During the investigation of aviation accidents, postmortem specimens from accident victims including blood, urine, and tissue are submitted to the Federal Aviation Administration's Civil Aerospace Medical Institute (CAMI) for toxicological analysis. The first, and perhaps most important, step in the analysis process is the initial screening of biological specimens for illicit, medically prescribed, and over-the-counter compounds that may be present and potentially be a cause and/or factor in the accident. Currently, our general unknown screening (GUS) procedure involves, in part, both gas chromatography-mass spectrometry (GC-MS) and liquid chromatography (LC) with both diode-array detection (DAD) and fluorescence detection. Both GC and LC techniques have inherent limitations that prevent the detection of certain types of compounds. The decreased specificity and sensitivity of LC-DAD has been an impediment to the existing GUS procedure. Therefore, our laboratory set out to develop and validate an LC-MS-MS procedure that is superior to LC-DAD. The limits of detection of 359 forensically important xenobiotics have been established following solid-phase extraction from whole blood and analysis by LC-MS-MS. Although whole blood was used as the matrix during instrument validation, the method has been successfully applied to both forensic urine and tissue specimens as well.
Assuntos
Toxicologia Forense/métodos , Drogas Ilícitas/metabolismo , Medicamentos sem Prescrição/metabolismo , Medicamentos sob Prescrição/metabolismo , Xenobióticos/metabolismo , Acidentes Aeronáuticos , Análise Química do Sangue , Cromatografia Líquida , Humanos , Drogas Ilícitas/sangue , Drogas Ilícitas/urina , Extração em Fase Sólida , Detecção do Abuso de Substâncias/métodos , Espectrometria de Massas em Tandem , Xenobióticos/sangue , Xenobióticos/urinaRESUMO
Cyproheptadine (Periactin) is a first-generation antihistamine available in over-the-counter cold medications and is used to treat allergic-type symptoms. Although antihistamines in general have long been known to cause serious side effects, especially when taken in overdose, few reports that specifically address cyproheptadine-related fatalities exist. A 42-year-old healthy female was found dead at her home with no anatomic cause of death and a recent history of suicidal ideations. Toxicology revealed cyproheptadine and citalopram in the femoral postmortem blood at concentrations of 0.49 and 2.3 mg/L, respectively. Vitreous, urine, and bile analysis were also performed, yielding concentrations of < 0.04 and 0.80 mg/L in the vitreous for cyproheptadine and citalopram, respectively; 0.23 and 8.2 mg/L in the urine; and 30.7 and 9.0 mg/L in the bile. The cause of death was determined to be cyproheptadine and citalopram intoxication, and the manner was ruled a suicide. Although cyproheptadine is widely available in the United States and Europe, there are only two published fatalities due to this antihistamine and only one that specifically cites blood and tissue concentrations. Therefore, this case study will be beneficial to the forensic toxicology community by providing additional information regarding postmortem interpretation.